15-Deoxyspergualin: Immunotherapy in solid organ and cellular transplantation

Transplantation Reviews

Volumn 10, Issue 3, 1996, Pages 160-174

  Kaufman, Dixon B ^a   Gores, Paul F ^b   Kelley, Susan ^b   Grasela, Dennis M ^b   Nadler, Steven G ^b   Ramos, Eleanor ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000173198     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-470X(96)80025-5     Document Type: Article

References (92)

1. Umeda Y, Moriguchi M, Ikai K, et al: Synthesis and antitumor activity of spergualin analogues. III Novel method for synthesis of opically active 15-deoxyspergualin and 15-deoxy-11-o-methylspergualin. J Antibiot 1987, 40:1316
2. Tepper MA, Petty B, Bursuker I, et al: Inhibition of antibody production by the immunosuppressive agent, 15-deoxyspergualin. Transplant Proc 1991, 23:328
3. Fujii H, Takada T, Nemoto K, et al: Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J Antibiot 1990, 43:213
4. Pai LH, Fitzgerald DJ, Tepper M, et al: Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 1990, 50:7750
5. Gannedahl G, Karlsson-Parra PA, Totterman TH, et al: 15-deoxyspergualin inhibits antibody production in mouse to rat heart transplantation. Transplant Proc 1993, 25:778
6. Dhingra K, Fritsche H, Murray JL, et al: Phase I and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995, 55:3060
7. Makino M, Fujiwara M, Watanabe H, et al: Immunosuppressive activites of deoxyspergualin. II. The effect on the antibody responses. Immunopharmacology 1987, 14:115
8. Alegre ML, Sattar HA, Herold KC, et al: Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation 1994, 57:1786
9. Sterbenz KG, Tepper MA: Effects of 15-deoxyspergualin on the expression of surface immunoglobulin in 70Z/3.12 murine pre-B cell line. Ann NY Acad Sci 1993, 685:205
10. Tepper MA, Nadler SG, Esselstyn J, et al: Deoxyspergualin inhibits κ light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-κB activation. J Immunol 1995, 155:2427
11. Matas AJ, Gores PF, Kelley SL, et al: Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. Clin Transplant 1994, 8:116
12. Jiang H, Takahara S, Kokado Y, et al: In vitro immunosuppressive effect: a comparitive study between deoxyspergualin and cyclosporin A on human lymphocyte responses. J Clin Lab Immunol 1990, 33:75
13. Takahara S, Jiang H, Takano Y, et al: The in vitro immunosuppressive effect of deoxyspergualin in man as compared with FK506 and cyclosporine. Transplantation 1992, 53:914
14. Fujii H, Takada T, Nemoto K, et al: Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro. Int J Immunopharm 1992, 14:731
15. Kawasaki C, Okamura S, Shimoda K, et al: In vitro study of deoxymethylspergualin on functions of lymphocytes and bone marrow cells from healthy volunteers. J Antibiot 1995, 48:243
16. Nishimura K, Tokunaga T: Mechanism of action of 15-deoxyspergualin. Immunology 1989, 68:66
17. Hoeger PH, Tepper MA, Faith A, et al: Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J Immunol 1994, 153:3908
18. Stevens RB, Ansite JD, Sutherland DER, et al: 15-Deoxyspergualin inhibits nitric oxide production in the BB/W rat: Mechanisms for inhibition of islet cell dysfunction in diabetes and transplantation. Cell Transplant 1994, 3:226 (abstr)
19. Hibbs JB, Taintor RR, Vavrin Z, et al: Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988, 157:87
20. Nadler SG, Tepper MA, Schachter BZ, et al: Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 1992, 258:484
21. Gething MJ, Sambrook J: Protein folding in the cell. Nature 1992, 355:33
22. DeNagel DC, Pierce SK: A case for chaperones in antigen processing. Immunol Today 1992, 13:86
23. Melnick J, Argon Y: Molecular chaperones and the biosynthesis of antigen receptors. Immunol Today 1995, 16:243
24. Baeuerle PA, Henkel T: Function and activsation of NF-κB in the immune system. Annu Rev Immunol 1994, 12:141
25. Grilli M, Chin JJ, Lenardo MJ: NF-κB and Rel: Participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993, 143:1
26. Hattori S, Hattori Y, Banba N, et al: Pentamethyl-hyroxychromane, vitamin E derivative, inhibits induction of nitric oxide synthase by bacterial lipoporysaccharide. Biochem Mol Biol Int 1995, 35:177
27. Bach FH, Robson SC, Winkler H, et al: Barriers to xenotransplantation. Nat Med 1995, 1:869
28. Chikaraishi T, Seki T, Takeuchi I, et al: Effect of short-term administration of deoxyspergualin in rat allogeneic renal transplantation. Transplant Proc 1992, 24:1631
29. Amemiya H, Suzuki S, Niiya S, et al: A new immunosuppressive agent, 15-deoxyspergualin, in dog renal allografting. Transplant Proc 1989, 21:3168,
30. Niiya S, Suzuki S, Hayashi R, et al: 15-Deoxyspergualin: A powerful rescue drug for rejection in canine kidney grafting. Transplant Proc 1989, 21:1076
31. Tanabe K, Takahashi K, Nemoto K, et al: Effect of deoxyspergualin on vascular rejection in canine kidney transplantation. J Urol 1994, 152:562
32. Reichenspurner H, Hildebrandt A, Human PA, et al: 15-Deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation 1990, 50:181
33. Corey RJ, Cutkomp J, Oberholser JH, et al: Prolongation of allograft and xenograft survival with 15-deoxyspergualin. Transplant Proc 1989, 21:530
34. Thies J, Walter P, Zimmermann F, et al: Prolongation of graft survival in allogenic pancreas and liver transplantation by (-)15-deoxyspergualin. Eur Surg Res 1987, 19:129
35. Kitabayashi K, Izumi R, Konishi K, et al: Increased graft survival by utilization of 15-deoxyspergualin in a canine pancreatic allotransplantation model. Eur Surg Res 1994, 26:54
36. Kaji J, Chou DT, Sutherland DE, et al: Synergistic effect of 15-deoxyspergualin and cyclosporine in prolonging survival of rat cardiac allografts. Transplant Proc 1994, 26:869
37. Kapelanski D, Perelman M, Faber L, et al: 15-Deoxyspergualin in primate heart transplantation. J Heart Transplant 1990, 9:668
38. Reichenspurner H, Hildebrandt A, Human PA, et al: 15-Deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation 1990, 50:181
39. Umezawa H, Ishizuka M, Takeuchi K, et al: Suppression of tissue graft rejection by spergualin. J Antibiot 1985, 38:283
40. Dickneite G, Schorlemmer H, Weinmann E, et al: Skin transplantation in rats and monkeys: Evaluation of efficient treatment with 15-deoxyspergualin. Transplant Proc 1987, 19:4244
41. Schorlemmer HU, Dickneite G, Seiler FR: Treatment of acute rejection episodes and induction of tolerance in rat skin allotransplantation by 15-deoxyspergualin. Transplant Proc 1990, 22:1626
42. Kamata K, Okubo M, Masaki Y, et al: Effect of 15-deoxyspergualin on the survival of thyroid allografts in mice. Transplant Proc 1989, 21:1099
43. Yuh DD, Morris RE: The immunopharmacology of immunosuppression by 15-deoxyspergualin. Transplantation 1993, 55:578
44. Holland EJ, Olsen TW, Sterrer J, et al: Suppression of graft rejection using 15-deoxyspergualin in the allogeneic rat penetrating keratoplasty model. Cornea 1994, 13:28
45. Walter PK, Dickneite G, Schorlemmer HU, et al: Prolongation of graft survival in allogeneic islet transplantation by (-) 15-deoxyspergualin in the rat. Diabetologia 1987, 30:38
46. Dickneite G, Schorlemmer HU, Walter P, et al: The influence of (±)-15-deoxyspergualin on experimental transplantation and its immunopharmacological mode of action. Behring Inst Mitt 1986, 80:93
47. Dickneite G, Schorlemmer HU, Sedlacek HH, et al: Suppression of macrophage function and prolongation of graft survival by the new guanidinic-like structure 15-deoxyspergualin. Transplant Proc 1987, 19:1301
48. Kaufman DB, Platt JL, Rabe FL, et al: Differential roles of Mac1 + cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts. J Exp Med 1990, 172:291
49. Kaufman DB, Platt JL, Sutherland DER: Elimination of islet allograft primary nonfunction by modulation of recipient alloimmunity. Surg Forum 1989, 40:367
50. Debray-Sachs M, Assan R, Bailey D, et al: Functional inhibition of isolated pancreatic cells, new technic for the detection of macrophage cytotoxicity. C R Acad Sci D [Sci Nat] 1978, 287:1161
51. Kaufman DB, Field MJ, Gruber SA, et al: Extended functional survival of murine islet allografts with 15-deoxyspergualin. Transplant Proc 1992, 24:1015
52. Kaufman DB, Gores PF, Field MJ, et al: Effect of 15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass. Diabetes 1994, 43:778
53. Kenmochi T, Mitamoto M, Mullen Y: Protection of mouse isle tisografts from nonspecific inflammatory damage by recipient treatment with nicotinamide and 15-deoxysoergualin. Cell Transplant 1996, 5:41
54. Nadler S: Personal communication, 1996
55. Farney AC, Xenos E, Sutherland DER, et al: Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant Proc 1993, 25:865
56. Xenos ES, Casanova D, Sutherland DE, et al: The in vivo and in vitro effect of 15-deoxyspergualin on pancreatic islet function. Transplantation 1993, 56:144
57. Jindal RM, Soltys K, Yost F, et al: Effect of deoxyspergualin on the endocrine function of the rat pancreas. Transplantation 1993, 56:1275
58. Gores PF, Field JF, Sutherland DE, et al: Synergistic interaction of 15-deoxyspergualin and cyclosporine to prolong the survival of rat islet allografts. Transplant Proc 1994, 26:745
59. Stephanian E, Lloveras JJ, Sutherland DER, et al: Prolongation of canine islet allograft survival by 15-deoxyspergualin. J Surg Res 1992, 52:621
60. Gores PF, Najarian JS, Stephanian E, et al: Insulin independence in type 1 diabetes after transplantation of unpurified islets from single donorwith 15-deoxyspergualin. Lancet 1993, 341:19
61. Leventhal JR, Flores HC, Gruber SA, et al: Evidence that 15-deoxyspergualin inhibits natural antibody production but fails to prevent hyperacute rejection in a discordant xenograft model. Transplantation 1992, 54:26
62. Marchman W, Araneda D, DemMasi R, et al: Prolongation of xenograft survival after combination therapy with 15-deoxyspergualin and total lymphoid irradiation in the hamster to rat cardiac xenograft model. Transplantation 1992, 53:30
63. Reichenspurner H, Human PA, Boehm DH, et al: Optimalization of immunosuppression after xenogeneic heart transplantation in primates. J Heart Transplant 1989, 8:200
64. Gill RG: The role of direct and indirect antigen presentation in the response to islet xenografts. Transplant Proc 1992, 26:642
65. Carty SE, Carroll PB, Rilo H, et al: Primary nonfunction of human pancreatic islet xenografts is murine strain dependent. Transplant Proc 1994, 26:780
66. Yabuuchi H, Nakajima Y, Segawa M, et al: Prominent prolongation of islet xenograft survival in combination therapy with FK506 and 15-deoxyspergualin. Transplant Proc 1991, 23:859
67. Ueno M, Nakaijima Y, Segawa M, et al: Immunosuppressive effect in combination therapy of cyclosporine A, FK506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. Transplant Proc 1992, 24:638
68. Henretta J, Pittman K, McFadden T, et al: Deoxyspergualin and rabbit antithymocyte globulin markedly prolong discordant pig pancreatic islet xenografts. Transplant Proc 1993, 25:412
69. Pittman K, Thomas J, Thomas F: Reduction of primary nonfunction in discordant pancreas islet xenografts. Transplant Proc 1992, 24:619
70. Jindal RM, Soltys K, Yost F, et al: Xenotransplantation of pig pancreatic islets to rat using 15-deoxyspergualin monotherapy. Transplant Proc 1994, 26:1108
71. Menger MD, Jäger S, Walter P, et al: The influence of (±)-15-deoxyspergualin on revascularization of xenogeneic transplanted islets of Langerhans. Transplant Proc 1990, 22:1631
72. Thomas FT, Tepper MA,Thomas JM,etal: 15-Deoxyspergualin: A novel immunosuppressive drug with clinical potential. Ann NY Acad Sci 1993, 685:175
73. Muindi JF, Lee S-J, Baltzer L, et al: Clinical pharmacology of deoxyspergualin in patients with advanced cancer. Cancer Res 1991, 51:3096
74. Havlin KA, Kuhn JG, Koeller J, et al: Deoxyspergualin: Phase I clinical, immunologic and pharmacokinetic study. Anticancer Drugs 1995, 6:229
75. Ohlman S, Zilg H, Schindel F, et al: Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. Transplant Int 1994, 7:5
76. Chan G, Canafax D, Light J, et al: Pharmacokinetics of deoxyspergualin in repeat renal transplant patients. Clin Pharmacol Ther 1995, 57:219 (abstr)
77. Kronbach T, Fischer V, et al: Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988, 43:630
78. Amemiya H, Suzuki S, Ota K, et al: A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. Transplantation 1990, 49:337
79. Amemiya H, Dohi K, Otsubo O, et al: Markedly enhanced therapeutic effect of deoxyspergualin on acute rejection when combined with methylprednisone in kidney recipients. Trans Proc 1991, 23:1087
80. Ohlman S, Gannedahl G, Tyden G, et al: Treatment of renal transplant rejection with 15-deoxyspergualin - A dose-finding study in man. Transplant Proc 1992, 24:318
81. Okubo M, Tamura K, Kamata K, et al: 15-Deoxyspergualin "rescue therapy" for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody (OKT3). Transplantation 1993, 55:505
82. Groth CG, Ohlman S, Ericzon BG, et al: Deoxyspergualin for liver graft rejection (letter). Lancet 1990, 336:626
83. Goodman GE, Hellstrom I, Brodzinsky L, et al: Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990, 8:1083
84. Ziegler LD, Palazzolo P, Cunningham J, et al: Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleuken-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 1992, 10:1470
85. Takahashi K, Yagisawa T, Sonda K, et al: ABO-incompatible kidney transplantation in a single-center trial. Transplant Proc 1993, 25:271
86. Gannedahl G, Ohlman S, Persson U, et al: Rejection associated with carlt appearance of donor-reactive antibodies after kidney transplantation treated with plasmapheresis and administration of 15-deoxyspergualin. A report of two cases. Transplant Int 1992, 5:189
87. Federlin K, Bretzel RG, Hering BJ: International Islet Transplant Registry. Newsletter 1995, 5:16
88. Wahoff DC, Papalois BE, Najarian JS, et al: Autologous islet transplantation to prevent diabetes after pancreatic resection. Ann Surg 1995, 222:562
89. Boudreaux JP, McHugh L, Canafax DM, et al: The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987, 44:376
90. Ricordi L, Zeng Y, Alejandro R, et al: In vivo effect of FK-506 on human pancreatic islets. Transplantation 1991, 52:519
91. Whiting PH, Woo J, Adama BJ, et al: Toxicity of rapamycin - A comparison and combination study with cyclosporine at immunotherapeutic dosage in the rat. Transplantation 1991, 52:203
92. Groth CG: Deoxyspergualin in allogeneic kidney and xenogeneic islet transplantation: Early clinical trials. Ann NY Acad Sci 1993, 685:193